Modalis Therapeutics Corporation [4883.T]
TOKYO, Apr 23 (Pulse News Wire) – Modalis Therapeutics Corporation (4883.T) completed the exercise of its 17th tranche warrants allocated to EVO FUND. Additionally, the company released monthly exercise activity details for April 2026.
In April, the total number of shares delivered was 3,780,000. A total of 37,800 warrants were exercised during the month. The exercise ratio relative to the total issuance of 192,000 warrants stood at 19.7%. As of the end of March, there were 37,800 unexercised warrants remaining (3,780,000). By the end of April, all unexercised warrants had been fully utilized, leaving zero outstanding. Detailed daily exercise activities in April included: - April 1: 20,000 shares transferred, exercising 200 warrants at ¥57 per warrant. - April 6: 220,000 shares transferred, exercising 2,200 warrants at ¥57 per warrant.
- April 8: 1,040,000 shares transferred, exercising 10,400 warrants at ¥54 per warrant. - April 14: 800,000 shares transferred, exercising 8,000 warrants at ¥53 per warrant. - April 16: 160,000 shares transferred, exercising 1,600 warrants at ¥54 per warrant. - April 23: 1,540,000 shares transferred, exercising 15,400 warrants at ¥53 per warrant. As of the end of March, the total number of issued shares was 92,354,098, including 63 treasury shares. Regarding the exercise limitations based on listing regulations, the combined number of attached shares was 3,780,000, while the number of listed shares at the time of issuance was 76,933,798. The exercise ratio adhering to the limitation was 4.9%.
For more detailed information on the issuance of the 17th tranche warrants, refer to the press release dated August 7, 2025.
🟢 Confidence: High AI-translated content.